- Home
- STEP vs GH Comparison
STEP vs GH Comparison
Compare STEP & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEP
- GH
- Stock Information
- Founded
- STEP 2007
- GH 2011
- Country
- STEP United States
- GH United States
- Employees
- STEP N/A
- GH N/A
- Industry
- STEP Finance/Investors Services
- GH Medical Specialities
- Sector
- STEP Finance
- GH Health Care
- Exchange
- STEP Nasdaq
- GH Nasdaq
- Market Cap
- STEP 4.6B
- GH 4.9B
- IPO Year
- STEP 2020
- GH 2018
- Fundamental
- Price
- STEP $53.04
- GH $49.14
- Analyst Decision
- STEP Buy
- GH Strong Buy
- Analyst Count
- STEP 7
- GH 20
- Target Price
- STEP $65.14
- GH $54.35
- AVG Volume (30 Days)
- STEP 791.2K
- GH 2.2M
- Earning Date
- STEP 08-07-2025
- GH 08-06-2025
- Dividend Yield
- STEP 2.56%
- GH N/A
- EPS Growth
- STEP N/A
- GH N/A
- EPS
- STEP N/A
- GH N/A
- Revenue
- STEP $1,174,830,000.00
- GH $773,996,000.00
- Revenue This Year
- STEP N/A
- GH $23.14
- Revenue Next Year
- STEP $21.23
- GH $21.42
- P/E Ratio
- STEP N/A
- GH N/A
- Revenue Growth
- STEP 65.09
- GH 28.20
- 52 Week Low
- STEP $40.07
- GH $20.14
- 52 Week High
- STEP $70.38
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- STEP 39.03
- GH 62.17
- Support Level
- STEP $51.80
- GH $48.00
- Resistance Level
- STEP $54.39
- GH $51.71
- Average True Range (ATR)
- STEP 1.59
- GH 2.67
- MACD
- STEP -0.75
- GH 0.39
- Stochastic Oscillator
- STEP 17.87
- GH 78.60
About STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.